Business Wire

NEUSTAR

14.8.2019 09:02:04 CEST | Business Wire | Press release

Share
Neustar: ‘Under the Radar’ DDoS Attacks Increase by 158 Percent in Q2, 2019 Compared to the Same Time Last Year

Small-scale Distributed Denial of Service (DDoS) attacks are becoming more frequent and sophisticated, according to new research from Neustar ’s Security Operations Centre (SOC). Released today, the Q2, 2019 Cyber Threats and Trends report reveals that between April and June of this year, over 75 percent of all attacks mitigated by Neustar were 5 Gigabits per second (Gbps) or less, while large attacks – those of 100 Gbps and over – decreased by 64 percent.

At first glance, the evolution of DDoS attacks on enterprises seems to follow a pattern. The overall number of attacks during Q2 2019 compared with the previous year grew by 133 percent, which, though down from last quarter’s 200% growth, is still high. Stepping outside an analysis of the numbers of attacks to their composition, however, shows some interesting changes, according to Neustar.

Small and secretive

DDoS attacks have long been considered overwhelming threats and are traditionally associated with high rates of traffic. Such attacks do continue to take place, but smaller and more carefully targeted incursions are growing in quantity, intensity and duration. Such attacks do not seek to saturate the network link – and draw unwanted attention in the process – but to degrade or disable specific infrastructure within the target. Such lower volume incursions may enable the perpetrator to get in and get out unnoticed, or allow the attack to continue for quite a long time undetected. In fact, the longest duration for a single attack in Q2 was nearly two days.

These small attacks pose a significant threat, as they fall below the typical threshold that enterprises with a “detect and alert” DDoS mitigation strategy might employ. An attacker could therefore affect targets ranging from infrastructure to individual servers with relative impunity.

The situation becomes more alarming when considering an enterprise’s ability to recognise such threats when they were underway. When asked how likely they would be to notice today’s most prevalent smaller attacks, a staggering 72 percent of CTOs, CISOs and Directors of Security from the Neustar International Security Council (NISC) answered very unlikely, somewhat unlikely or somewhat likely. The remaining 28 percent of respondents felt it was very likely that they would notice a small-scale DDoS attack.

“With the rise of smaller DDoS attacks going under the radar, now is the time for organisations to deploy an ‘always on’ DDoS mitigation service that is constantly monitoring traffic to ensure threats of all sizes are detected, managed and diffused,” said Rodney Joffe, Senior Vice President, Senior Technologist and Fellow at Neustar.

“Now, with most of today’s attacks directed at specific services, gateways and applications – therefore requiring less traffic to bring it down – a greater level of understanding from businesses to determine the protection they need is essential. The first stage of this is to determine what is valuable, not what is vulnerable. One of the best ways to separate vulnerability from value is to create a ‘risk register’ that starts from the inside and focuses on your most critical business assets,” Joffe added.

A complimentary copy of The Neustar Q2’19 Cyber Threats and Trends Report is available here .

- ENDS -

About Neustar, Inc.

Neustar, Inc. is a leading global information services provider driving the connected world forward with responsible identity resolution. As a company built on a foundation of Privacy by Design, Neustar is depended upon by the world’s largest corporations to help grow, guard and guide their businesses with the most complete understanding of how to connect people, places and things. Neustar’s unique, accurate and real-time identity system, continuously corroborated through billions of transactions, empowers critical decisions across our clients’ enterprise needs. More information is available at https://www.home.neustar .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye